Stemina Biomarker Discovery develops and commercializes molecular biomarkers to improve drug safety and human health.
Stemina Biomarker Discovery, Inc., a metabolomics company, focuses on the discovery, development, and commercialization of molecular biomarkers to improve drug safety and human health. The company works on collaborative research projects and joint development agreements with strategic partners to develop drugs, identify targets, and discover molecular biomarkers for the diagnosis of diseases and customized treatment. It provides metabolomics and mass spectrometry services, as well as develops diagnostic biomarkers. The company's cell-based assays arise from the strategic convergence of technologies, such as human embryonic stem (hES) cells and metabolomics. It uses mass spectrometry to analyze the small molecules secreted by hES, heart, and neural cells in response to drugs, injury, or disease. Stemina Biomarker Discovery, Inc. was founded in 2006 and is based in Madison, Wisconsin.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 23, 2015 | Grant | $2.60M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institutes of Health | — | Grant |